Dr Erica Mayer Erica Mayer presents results of the TRADE study - dose escalation of adjuvant abemaciclib from 50 mg bid to 150 mg bid over the first 12 wks reduced drug discontinuation rates and allowed most pts to reach the target dose.

NATALEE update Kevin Kalinsky, MD, MS, FASCO ✅Consistent benefit across menopausal status and age ✅Manageable safety profile across all subgroups ⬇️Ribo discontinuation due to AE in younger premenopausal pts ✅Maintained QoL for all subgroups #ASCO25 #bcsm Oncology Brothers OncoAlert

Congrats to Ayal Aizer and team on this important ph 3 RCT presented at ASCO today! -Solid tumors (except SCLC) -5-20 brain metastases -SRS v HA-WBRT ➡️fewer symptoms ➡️less interference in function ➡️no decrement in OS Favors SRS over WBRT

SERENA-6: switch to camizestrant + cdk4/6i on emergence of ESR1 mutation by ctDNA in the absence of radiographic PD ~7 month gain in PFS -substantial and compelling delay in time to deterioration of global health status -OS not mature

TBCRC 040 (PREDICT-DNA trial): Dr. Natasha Hunter presents - -HER2+ or TN pts with MRD assay after NAT and pre surgery -in TNBC, ctDNA MRD status distinguished between those with RD who had excellent vs poor prognosis Heather Parsons Translational Breast Cancer Research Consortium Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy) Ben Ho Park

Fabulous discussion from Dr. Alexandra Thomas on the evolving evidence for ctDNA across the continuum of breast cancer. Roadmap to understand when and how to use ctDNA in the clinic and what studies are still very much needed before changing practice Breast International Group

Happening Now! #ASCO25 Poster Session 👉 Use of baseline plasma circulating tumor DNA (#ctDNA) to predict duration of endocrine therapy and CDK4/6 inhibitor therapy and to analyze intrinsic vs acquired #EndocrineResistance. Pietro De Placido 📍Abs 1075 | Poster Bd 54 | Jun 2,

Check out my summary of our poster at #ASCO25 in collaboration with Foundation Medicine ! 🔍ERBB2 amplification predicts benefit from T-DXd and T-DM1 beyond clinical HER2 IHC status; technologies that better quantify HER2 dependence are needed to guide selection btw HER2 directed

Happening Now! #ASCO25 Poster Session: #CirculatingTumorDNA (#ctDNA) and late recurrence in high-risk, hormone receptor-positive, HER2-negative #BreastCancer: An updated analysis of the #CHiRP study. #TaeKyungRobynYoo Heather Parsons Nancy Lin, MD 📍Abstract: 3055 | Poster Bd 370 | Hall

This is data many of who treat the highest risk young patients (N2-3) have waited for for a while! This ahould have been an oral #ASCO2025 Ann Partridge MD, MPH #bcsm

Pleased to share the first series of pts who experienced recurrence on adjuvant abemaciclib+ET: ➤ 9.2% (15/163) recurred ➤ 50% ER loss post-tx ➤ 90% TP53-pathway alterations post-tx ➤ Median 1L m+ tx duration: 3.0 mo (IQR 1.6–5.0) shorturl.at/ZnMI5

The outpouring of support from the oncology community has been tremendously moving. Thank you to all who are keeping Felix’s legacy alive. Can’t wait to see what Dr. Wala does next!

Chemotherapy can save lives, but it can also come with challenges like #PeripheralNeuropathy. Ting Bao, MD, MS, (Ting Bao, MD) co-director of the Dana-Farber Zakim Center breaks down #ChemotherapyInducedPeripheralNeuropathy. Watch the webinar to learn about the causes, symptoms, risk

Study that went under the radar at ASCO. WBRT with hippocampal sparing and memantine versus SRS for 5-20 brain metastases. Same Overall survival, Lower Symptom Burden and Life Interference with SRS, Better KPS with SRS. New standard of care! Congrats Dr. Aizer on this amazing

📢Reminder! The #HarvardBreastCancerCourse is next week on July 17 & 18! Check out our hashtag to see past speakers and topics. Register today to attend in person or virtually ⬇️⬇️ learn.hms.harvard.edu/programs/breas…

Now published! Phase 1/2 palazestrant (OP-1250) monotherapy in ER+ MBC -at RP2D 120 mg/d -mPFS 4.8 mo overall, 5.6 mo in ESR1mut -in “EMERALD eligible” pts (1-2 prior ET for MBC +/- 1L chemo), mPFS > 7 mo regardless of ESR1 status pubmed.ncbi.nlm.nih.gov/40598566/

Cancer patients and those who care about them need to appreciate how the administration is threatening cancer research and innovation. How Trump Killed Cancer Research | WIRED wired.com/story/how-trum…

There is still time to register for the ASCO/SNO CNS mets meeting! -Aug 14-16 in Baltimore, MD - Keynote speakers Helena Yu Dr Marcela Maus -panels with academic/industry leaders, FDA, cooperative grps, patient advocates -great session lineup soc-neuro-onc.org/SNOASCO2025/SN…